Trial intelligence / Profile preview

Phase III study of simeprevir versus placebo with peginterferon alfa-2a and ribavirin in treatment-naive genotype 1 hepatitis C

2010-020444-36Phase 3Completed

Sponsor

Janssen Pharmaceutical

Start

Dec 2010

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1